Vor Biopharma’s (VOR) “Neutral” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their neutral rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report sent to investors on Friday, MarketBeat reports. Several other research firms have also issued reports on VOR. Wedbush restated a “neutral” rating and set a $0.40 price target (down from $7.00) on shares of Vor Biopharma […]
HC Wainwright reiterated their neutral rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report sent to investors on Friday, MarketBeat reports. Several other research firms have also issued reports on VOR. Wedbush restated a “neutral” rating and set a $0.40 price target (down from $7.00) on shares of Vor Biopharma […]
